Ipamorelin UK import rules for personal use

The narrow answer is that UK medicines law contains an express exemption for a person who imports a medicine to administer to themselves or to a member of their own household, and that exemption covers ipamorelin the same way it covers any other medicinal product. Regulation 17(1) of the Human Medicines Regulations 2012 says a person may not import a medicinal product into Great Britain without a manufacturer's licence, then regulation 17(6) states that the requirement "does not apply to a person who imports a medicinal product for administration to himself or herself or to any other person who is a member of that person's household"^[2]. That is where the personal-import question begins and ends. Selling it, supplying it or advertising it in the UK is a separate matter, and so is what a Border Force officer does when a parcel gets opened.

This page describes the law and the enforcement pattern. It is not a recommendation. In the UK, ipamorelin is classified as an unauthorised medicinal product: it holds no marketing authorisation, there is no controlled human safety dataset behind it, and there is no regulated supply chain. The ipamorelin peptide page covers what the evidence does and does not show, the UK regulation hub sets the wider frame, and the UK entry for ipamorelin tracks the current status. What follows is the import question on its own.

Regulation 17(6): the personal-use carve-out

Regulation 17(1) is the licensing rule. It says a person may not manufacture, assemble or import a medicinal product into Great Britain except in accordance with a manufacturer's licence^[2]. Regulation 17(6) then lifts personal imports out of that requirement. The wording turns on who the product is for, not on quantity, not on paperwork, and not on whether the product is licensed. If you import ipamorelin to administer to yourself or to someone in your household, regulation 17(1) does not apply to you.

Set that against the route a business has to take. The MHRA's guidance on importing a human medicine is written for wholesalers and manufacturers. To bring in an unlicensed medicine you need either a Manufacturer's Specials Licence or a Wholesale Dealer's Licence depending on the country of origin, and you have to notify the MHRA of your intent to import before the medicine arrives. In the agency's own words, "you can only proceed with the import if the MHRA does not object to it"^[5]. There is no matching consumer scheme, and that gap is not an oversight. It is why the personal exemption in regulation 17(6) has to exist at all.

One distinction is worth keeping straight, because forums blur it constantly. The Home Office personal-import policy, the one with the three-month supply ceiling and the letter from a prescriber, applies to controlled drugs, which the guidance defines as "drugs named in the misuse of drugs legislation"^[7]. Ipamorelin is not a controlled drug. It is an unauthorised medicine, which sits under a different Act, so the quantity thresholds people quote from the controlled-drugs rules do not transfer to it. If a number you are relying on came from a travel-with-medicine page, check which statute it belongs to before you lean on it.

Why a vial of ipamorelin is a medicine at all

This is where the grey market thinks the "research use only" label does more work than it does. Regulation 2 defines a medicinal product two ways. The presentation limb catches "any substance or combination of substances presented as having properties of preventing or treating disease in human beings". The function limb catches any substance that "may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action"^[1].

Stripping the health claims off a listing can dodge the presentation limb. It does nothing to the function limb. Ipamorelin is a growth-hormone secretagogue: it binds the ghrelin receptor on the pituitary and triggers a pulse of growth-hormone release, which is a pharmacological action on a physiological function and the entire reason anyone buys it. The mechanism section of the peptide page sets out that pharmacology in full. A sticker reading "not for human consumption" is a commercial hedge, not a regulatory category that turns the vial into something other than a medicine.

What stays illegal: selling, supplying, advertising

Regulation 46 is direct: "A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product"^[3]. A product is unauthorised when no UK marketing authorisation, certificate of registration or traditional herbal registration is in force for it. No ipamorelin product holds any of those. So the vendor shipping to a UK address, the clinic offering an injection and the reseller splitting a vial in a group chat are all on the wrong side of regulation 46, even where the person receiving the vial is covered by the personal-import exemption.

Advertising is caught separately. Regulation 279 prohibits publishing an advertisement in Great Britain for a medicinal product unless a marketing authorisation or an equivalent registration is in force^[4]. A UK site describing ipamorelin as a way to raise growth hormone, improve recovery or aid sleep is advertising an unauthorised medicine, whatever disclaimer sits in the page footer. The asymmetry is the point: the buyer's position and the seller's position are governed by different regulations, and the law puts the weight on the supply side.

What customs actually flags

Regulation 17(6) exempts you from needing a manufacturer's licence. It does not require Border Force to let a parcel through. The MHRA and Border Force run joint interception work at the UK border, most visibly through the recurring Operation Pangea. Pangea XVIII ran from 10 to 23 March 2026 across roughly 90 countries and territories, and the two agencies seized over 2 million doses of illicit medicines with a stated value of £4.6 million^[6]. The MHRA's framing was blunt: "taking medicines obtained from unregulated sources can lead to serious harm."

For a personal parcel the realistic outcome is a seizure and a letter, not a prosecution. Enforcement effort goes at the supply side, because that is where regulations 46 and 279 give the agency something to charge. Postal interception is the cheap way to disrupt a vendor's business model. If a vial vanishes between a customs shed and your door, the likely result is that you have lost the money, with no consumer-protection route to recover it, because the sale was not lawful at the seller's end.

It is worth being clear about what the exemption does not do. Regulation 17(6) is a defence to one licensing requirement. It is not a statement that the product is safe, that the contents match the label, or that a customs officer has to accept your account of who the parcel is for. Bulk quantities, repeat shipments to the same address and packaging that reads like resale stock all invite a different reading, and the regulation section of the ipamorelin page tracks how the picture shifts across the other jurisdictions we cover.

The grey-market reality, without the endorsement

We do not recommend vendors for compounds that are unauthorised medicines, and this page is not the exception. What we will state plainly is the supply picture. Ipamorelin sits on the World Anti-Doping Agency Prohibited List under section S2, the peptide-hormones and growth-factors category, grouped with the other growth-hormone secretagogues and releasing peptides^[8]. S2 substances are prohibited at all times, in and out of competition, so for any athlete under the World Anti-Doping Code a positive test is an anti-doping rule violation regardless of when the sample was taken.

So the import question turns out to be the least interesting part. A lawful personal import of an unlicensed product still leaves you with a vial from a supplier operating outside medicines law: no batch release, no pharmacopoeial identity testing and no adverse-event reporting route. Independent testing of grey-market peptide vials routinely finds purity and identity failures, and there is no published long-term human safety dataset for ipamorelin to fall back on. The what we do not yet know section goes through the gaps in the evidence base, which are wider than the marketing suggests.

None of this is specific to ipamorelin. The same three regulations catch every unauthorised peptide sold to UK consumers, which is why our UK entries for compounds like BPC-157 and the wider UK regulation hub read almost identically. The compound changes. The licensing question does not. What differs between them is the depth of the evidence and the amount of independent purity testing anyone has run, and on both counts ipamorelin is thinner than its reputation.

Practical context

If you are a UK reader trying to gauge your exposure, the shape is this. Importing ipamorelin for your own use sits inside an express statutory exemption. Selling or supplying it to anyone else does not, and advertising it does not. Neither position makes the product authorised, safe or verified in its contents. The UK page for ipamorelin is where we keep the current status current.

Regulations change and enforcement priorities change faster. Verify the live text of the Human Medicines Regulations 2012 on legislation.gov.uk before relying on any of the above, and if the distinction matters for a decision you are about to make, take it to a clinician and, where the legal position is the sticking point, to a solicitor. We are neither.